Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Changing Trends in Cardiovascular Disease Burden in North Africa and the Middle East, 1990-2023: A Joinpoint Analysis of GBD 2023 Data.

Journal of clinical medicine·2026

Same author

Streptococcal toxic shock syndrome caused by ST525 Streptococcus dysgalactiae subsp. equisimilis with genomic characterization of virulence and antimicrobial resistance.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2026

Same author

Clinical Characteristics and Therapeutic Dilemmas in Nocardiosis: Insights from a Case Series.

International journal of antimicrobial agents·2026

Same author

International Trends in Head and Neck Cancer Mortality.

JAMA otolaryngology-- head & neck surgery·2026

Same author

<i>Digital Tattoos</i> in Infectious Diseases Management.

Open forum infectious diseases·2026

Same author

Accuracy of 0.25 µg/mL-Interval MIC Measurement of Vancomycin Among Staphylococcus aureus: a Pilot Study.

Clinical laboratory·2026

Search research articles

Related Experiment Video

Updated: Sep 1, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

Cefepime-induced neurotoxicity: systematic review.

Gozun Maan¹, Koichi Keitoku¹, Nobuhiko Kimura¹

¹Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI 96813, USA.

The Journal of Antimicrobial Chemotherapy

|August 16, 2022

Summary

Cefepime-induced neurotoxicity (CIN) is a recognized complication, often linked to renal dysfunction and occurring within days of starting cefepime. Symptoms improve with dose adjustment, highlighting the need for careful patient selection and dosing.

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Pentylenetetrazole-Induced Kindling Mouse Model

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Related Experiment Videos

Last Updated: Sep 1, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Pentylenetetrazole-Induced Kindling Mouse Model

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Area of Science:

Pharmacology
Neurology
Clinical Medicine

Background:

Cefepime-induced neurotoxicity (CIN) is a known clinical issue without established diagnostic criteria or specific tests.
Understanding CIN's characteristics is crucial for effective patient management.

Conclusions:

This review synthesizes current knowledge on CIN, emphasizing the lack of diagnostic criteria and routine drug monitoring.
Careful patient selection and appropriate cefepime dosing are essential to prevent CIN.
Further research is needed to establish diagnostic criteria and improve monitoring for CIN.